RxDoctor Payments Data

Janavi Rao, MD

Pain Medicine · Tucson, AZNPI 1356754063

Payments from drug & device makers

$8,358in general payments, 2019–2025

Across 194 payments — averaging $43.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Nalu Medical, Inc.$2K
  • Medtronic$577
  • Collegium Pharmaceutical, Inc.$440
  • Averitas Pharma Inc.$425
  • Abbott$260
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$2,80234%
  • Food & beverage$5,55666%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,358 in reported general payments places this provider in the 65th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$86,166
Medicare patients
180
Services billed
959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate28$14,055
Pregabalin228$5,345
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen131$4,531
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen99$3,347
Gabapentin219$2,939
Morphine Sulfate ErMorphine Sulfate105$2,588
Oxycodone Hcl138$1,886
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$1,860
Cyclobenzaprine Hcl97$1,612
Tizanidine Hcl80$1,381
Duloxetine Hcl63$1,046
Tramadol Hcl ErTramadol Hcl11$1,037
Tramadol Hcl81$544
Celecoxib19$516
Baclofen22$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$440$14,05528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →